1Maquelin KN,Berckmans R J,Nieuwland R,Schaap MC,ten Have K,Eijsman L,et al.Disappearance of glycoprotein Ib from the platelet surface in pericardial blood during cardiopulmonary bypass J[J].Thorac Cardiovasc Surg,1998,115(5):1160-1165.
7Parolari A,Guarnieri D,Alamanni F,Toscano T,Tantalo V,Gherli T,et al.Platelet function and anesthetics in cardiac surgery:an in vitro and ex vivo study[J].Anesth Analg,1999,89(1):26-31.
1[1]Parolari A, Guarnieri D, Alamanni F et al. Platelet function and anesthetics in cardiac surgery: an in vitro and ex vivo study. Anesth Analg,1999,89:26
2[2]Wahba A, Black G, Kosch M et al. Cardiopulmonary bypass leads to a preferential loss of activated platelets:a flow cytometric assay of platelet surface antigens. Eur J Cardiothorac Surg, 1996 ,10 : 768
3[3]Sedlmay P, Grobhapt B, Muntean W. Flow cytometry detection of intracellular platelet antigens. Cytometry, 1996,23:284
4[4]Kestin A, Valeri R, Khuri S et al. The platelet function defect of cardiopulmonary bypass. Blood, 1993,82:107
5[5]Storck J, Hllger N, Zimmermann R. The influence of heparin and protamine sulfate on platelet ADP and platelet factor 4 release and the expression of glycoprotein Ⅱb/Ⅲa. Haemostasis, 1994,34:358
6[6]Ammar T, Fisher C. The effects of heparinase 1 and protamine on platelet reactivity. Anesthesiology, 1997,86:1382
7[7]Toshiaki M, Peter J, Olson F et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg, 1998,87:781
8Sedlmay P,Grobhapt B,Muntean W.Flow cytometry detection of intracellular platelet antigens[].Cytometry.1996
9Primack C,Walenga J,Koza M,et al.Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations[].The Annals of Thoracic Surgery.1996
10Kozek-Langenecker SA,Masaki T,Mohammad H,et al.Fibrinogen fragments and platelet dysfunction in uremia[].Kidney International.1999
3Gil W.Infiammo-coagulatory response, extrinsic pathway thrombin generation and a new theory of activated clotting time interpretation [J].Perfusion, 2001,16( 1 ):27
4Arnold P, Jackson S, Wallis J, et al.Coagulation factor activity duringneonatal extra-corporeal membrane oxygenation [J].Intensive Care Med, 2001,27 (8):1395
5Muntean W. Coagulation and anticoagulation in extracorporeal membrane oxygenation[J]. Artif Organs, 1999,23 ( 11 ) :979
6Cheung PY, Sawicki G,Salas E, et al.The mechanisms of platelet dysfunction during extracorporeal membrane oxygenation in critically ill neonates[J].Crit Care Med,2000,28 (7) :2584
7Baird CW, Zurakowski D,Robinson B, et al.Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival[J]. Ann Thorac Surg, 2007, 83(3):912
8Nankervis CA, Preston TJ,Dysart KC, et al. Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation[J]. ASAIO J, 2007,53 ( 1 ): 111
9Scott LK, Grier LR, Conrad SA. Heparin-indueed thrombocytopenia in a pediatric patient receiving extraeorporeal membrane oxygenation managed with argatrobandouble dagger[J].Pediatr Crit Care Med, 2006,7 (5):473
10Young G, Yonekawa KE,Nakagawa p, et al. Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits [J].Perfusion, 2004,19 (5):283
